Floatz logo

Eloxatin

Adverse Event

Sun Yat-sen UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Adverse Event cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Lei Li
Phase 3B
Acalabrutinib
Polish Lymphoma Research Group
Phase 2B
Solu-Cortef
Mahidol University
Phase 2CCC
Tucidinostat
Sun Yat-sen University
N/AD
Azacitidine
Sun Yat-sen University
N/AD

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →